Aurinia Pharmaceuticals (AUPH) PT Raised to $11 at RBC Capital
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $15.47 +1.91%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $11.00 (from $9.00) while maintaining a Outperform rating.
- no surprises out of the results
- remains on track in its Ph. III lupus nephritis trial
- updated model on positive IP developments for voclosporin
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Petronet LNG Ltd. (PLNG:IN) PT Raised to INR310 at ICICI Securities
- LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
